📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
Below are the financial statements of Summit Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
Below are the financial statements of Summit Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 104.86a | 71.43a |
| Restricted cash | 0.33a | 0a |
| Short-term investments | 307.49a | 114.82a |
| Prepaid expenses and other current assets | 10.52a | 2.62a |
| Research and development tax credit receivable | 0.56a | 0.85a |
| Total current assets | 423.75a | 189.71a |
| Non-current assets | — | — |
| Property and equipment, net | 0.25a | 0.2a |
| Operating lease right-of-use assets | 7.14a | 5.86a |
| Goodwill | 1.86a | 1.89a |
| Research and development tax credit receivable | 0.7a | 0.96a |
| Other assets | 1.85a | 4.32a |
| Total assets | 435.56a | 202.95a |
| Liabilities and stockholders’ equity | — | — |
| Current liabilities | — | — |
| Accounts payable | 4.64a | 2.67a |
| Accrued liabilities | 19.55a | 8.78a |
| Accrued compensation | 11.98a | 5.43a |
| Operating lease liabilities, current portion | 3.77a | 2.81a |
| Other current liabilities | 1.8a | 0.72a |
| Total current liabilities | 41.73a | 20.41a |
| Non-current liabilities | — | — |
| Operating lease liabilities, net of current portion | 3.45a | 3.29a |
| Other non-current liabilities | 1.63a | 1.56a |
| Promissory note payable to a related party | 0a | 100a |
| Total liabilities | 46.81a | 125.26a |
| Stockholders’ equity | — | — |
| Preferred stock | 0a | 0a |
| Common stock | 7.38a | 7.02a |
| Additional paid-in capital | 1,598.23a | 1,066.38a |
| Accumulated other comprehensive loss | -2.29a | -2.45a |
| Accumulated deficit | -1,214.57a | -993.26a |
| Total stockholders' equity | 388.75a | 77.69a |
| Total liabilities and stockholders' equity | 435.56a | 202.95a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Summit Therapeutics’s data sources below and access millions more through our Disclosure Search.